Today marks a milestone in the path toward availability of kids’ COVID vaccines. The FDA’s advisory panel on vaccines, VRBPAC, voted that the benefits outweighed the risks for Pfizer’s new kids-only vaccine for ages 5 to 11.
Today marks a milestone in the path toward availability of kids’ COVID vaccines. The FDA’s advisory panel on vaccines, VRBPAC, voted that the benefits outweighed the risks for Pfizer’s new kids-only vaccine for ages 5 to 11.
No comments:
Post a Comment